Five Stocks Griffin Securities' Keith Markey Thinks Could Double or Triple

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 12 March 2015 12:50

For Keith Markey of Griffin Securities, the science is paramount. Without understanding the canadian generic cialis underlying basis for activity, safety and where to get viagra cheap efficacy, there's just no betting on a biotech stock.

Read more...
 

How to Beat the viagra vs cialis vs levitra which is better Herd Mentality: Highline's Michael Higgins

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 26 February 2015 15:04
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island.
Read more...
 

Immuno-Oncology Promises Continued Wealth and canadian pharmacy discount code viagra Health: LifeTech Capital's Stephen Dunn

Print E-mail
By Staff - The Life Sciences Report   
Thursday, 19 February 2015 15:38

Immuno-oncology disabling cancer's defenses so that a patient's own immune system can seek it out and brand cialis for sale destroy it took center stage in the drug development world in 2014.

Read more...
 

Bloom Burton's David Martin Zeroes In on Under-the-Radar Biotech

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 12 February 2015 16:26

Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and best price zithromax biotech companies based in Canada, where resource stocks have absorbed so much investment capital that many healthcare names have remained hidden and indian cialis generic undervalued.

Read more...
 

Capture Growth with Baskets of Biotechs: LifeSci Advisors' Andrew McDonald

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 05 February 2015 19:01
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development.
Read more...
 

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here?

Print E-mail
By Tracy Salcedo-ChourrĂ© of The Life Sciences Report   
Thursday, 29 January 2015 18:14
At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and buy now viagra found every reason to believe its good health would continue into 2015 and beyond.
Read more...
 

What's Next for Biotech in 2015?

Print E-mail
By The Life Science Report   
Thursday, 15 January 2015 08:42
Are life sciences stocks in a bubble? Will this be the year biotech overshadows big pharma?
Read more...
 

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off

Print E-mail
By Sharon di Stefano   
Monday, 12 January 2015 19:19

When peer-reviewed scientific articles publish, especially for investigational medicine, doctors and buy nexium online investors take notice. Few other accolades are held in such high esteem.

Read more...
 

Where Do Cures Reside? Morrie Ruffin and female viagra 2012 Michael Werner of the Alliance for Regenerative Medicine Think the Answer Is in Regenerative Medicine

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 08 January 2015 18:07

The practice of medicine is being transformed. The journey has been arduous, but revolutionary stem cell, gene and buy orlistat immunocellular therapies are rapidly moving toward pivotal milestones—and investors in the space should strap in for a rewarding joy ride.

Read more...
 

Q&A: Actinium Pharmaceuticals Inc. CEO Eyes Orphan Drug Application for Flagship Drug

Print E-mail
By M.E.Garza   
Wednesday, 07 January 2015 00:00

Actinium Pharmaceuticals Inc. a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced last month that the US Food and buy vibramycin Drug Administration (FDA) had granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60.

Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 50

Newsletter

BioMedReports Ocata Successfully Completes Dosing in Phase 1/2 RPE Studies; Capricor Completes Enrollment of Phase II Clinic... http://t.co/7X8xL6MZv7
8hreplyretweetfavorite
BioMedReports Can Fite Biopharma Ltd (ADR) NYSEMKT CANF) Slumps On Drug Trial Failure: Biotechnology Company Can Fite Bioph... http://t.co/uJyi3bOgmN
12hreplyretweetfavorite
BioMedReports Orexigen Therapeutics, Inc. (NASDAQ:OREX) stock surges as Mysimba gets European approval: Orexigen Therapeuti... http://t.co/kx3IQxiSKV